Geron/$GERN
1D1W1MYTD1Y5YMAX
Capital at risk
About Geron
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
- Ticker
- $GERN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 258
- Headquarters
- Foster City, United States
- Website
- www.geron.com
Geron Metrics
BasicAdvanced
$880M
-
-$0.10
0.59
-
Price and volume
Market cap
$880M
Beta
0.59
52-week high
$2.01
52-week low
$1.04
Average daily volume
11M
Financial strength
Current ratio
6.915
Quick ratio
5.038
Long term debt to equity
0.554
Total debt to equity
0.559
Interest coverage (TTM)
-1.17%
Profitability
EBITDA (TTM)
-34.799
Gross margin (TTM)
58.50%
Net profit margin (TTM)
-33.05%
Operating margin (TTM)
-17.25%
Revenue per employee (TTM)
$790,000
Management effectiveness
Return on assets (TTM)
-4.11%
Return on equity (TTM)
-28.28%
Valuation
Price to revenue (TTM)
4.478
Price to book
4.03
Price to tangible book (TTM)
4.03
Price to free cash flow (TTM)
-7.982
Free cash flow yield (TTM)
-12.53%
Free cash flow per share (TTM)
-0.172
Growth
Revenue change (TTM)
24.39%
Earnings per share change (TTM)
-23.63%
3-year revenue growth (CAGR)
668.90%
10-year revenue growth (CAGR)
18.80%
3-year earnings per share growth (CAGR)
-34.58%
10-year earnings per share growth (CAGR)
29.57%
What the Analysts think about Geron
Analyst ratings (Buy, Hold, Sell) for Geron stock.
Analyst projections of the future price of Geron stock.
Bulls say / Bears say
Second-quarter net product revenue of $57.48 million topped the $55.21 million consensus and grew 17% year-over-year and 11% sequentially, reflecting strong RYTELO adoption (Reuters)
Management indicated it expects to finish 2026 at the mid-to-high end of its $220 million–$240 million RYTELO revenue guidance range, underscoring confidence in sustained commercial momentum (Reuters)
Operating expenses in the first half of 2026 fell 4% year-over-year while net revenue rose 24%, demonstrating disciplined cost control and improving operating leverage (Reuters)
Q2 adjusted EPS loss of $0.02 per share missed the consensus by $0.01, highlighting Geron’s continued unprofitability despite revenue growth (Reuters)
Gross-to-net deductions rose to 20.7% in Q2 from 15.3% a year earlier, squeezing net realized revenue and indicating higher rebates and chargebacks pressure on margins (Reuters)
Key pipeline catalysts are long-dated, with the myelofibrosis program’s major readout not expected for years, delaying potential label expansion and leaving a multi-year gap before new clinical data (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2026.
Geron Financial Performance
Revenues and expenses
Geron Earnings Performance
Company profitability
Upcoming events
No upcoming events
Geron News
AllArticlesVideos
Funds containing Geron
AllEURUSDGBP
Fund name | Fund size | $GERN weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.08% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.07% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.